Ayr Wellness Inc. (OTCMKTS:AYRWF - Free Report) - Stock analysts at Roth Capital reduced their FY2024 EPS estimates for shares of Ayr Wellness in a research note issued on Wednesday, November 13th. Roth Capital analyst W. Kirk now expects that the company will earn ($1.40) per share for the year, down from their previous forecast of ($1.22). Roth Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Ayr Wellness' current full-year earnings is ($1.30) per share. Roth Capital also issued estimates for Ayr Wellness' Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.32) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.23) EPS.
Other analysts have also issued research reports about the stock. Roth Mkm lowered their price target on shares of Ayr Wellness from $3.50 to $3.00 and set a "buy" rating for the company in a report on Thursday. Atb Cap Markets lowered Ayr Wellness from a "hold" rating to a "strong sell" rating in a research report on Wednesday, November 13th.
Read Our Latest Research Report on Ayr Wellness
Ayr Wellness Trading Down 1.3 %
Shares of OTCMKTS AYRWF opened at $0.77 on Monday. Ayr Wellness has a 1-year low of $0.71 and a 1-year high of $4.09. The company has a 50-day moving average of $1.82 and a two-hundred day moving average of $1.98. The company has a market cap of $87.90 million, a PE ratio of -0.35 and a beta of 2.00. The company has a current ratio of 1.59, a quick ratio of 0.67 and a debt-to-equity ratio of 0.76.
About Ayr Wellness
(
Get Free Report)
Ayr Wellness Inc operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names.
Read More
Before you consider Ayr Wellness, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ayr Wellness wasn't on the list.
While Ayr Wellness currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
